• 1
    Maynard JE, Kare MA, Alter MJ, Hadler SC. Control of hepatitis B ly immunization: global perspective. In: ZuckermanAJ, ed. Viral hepatitis and liver disease. New York: Liss, 1988: 967969.
  • 2
    Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: epidemiologic considerations. HEPATOLOGY 1982; 2: S21S26.
  • 3
    Margolis HS, Alter MJ, Hadler SC. Hepatitis B. Evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 8492.
  • 4
    Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis Be antigenpositive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312323.
  • 5
    Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. The effect of recombinant alpha2 interferon in Chinese HBsAg carrier children. Lancet 1987; 2: 877880.
  • 6
    Lok ASF, Lai CL, Wu PC, Leung EKY. Long-term follow-up in a randomised controlled trial of recombinant α2 interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 6: 298302.
  • 7
    Lai CL, Lin HJ, Lau JYN, Lok ASF, Wu PC, Lau JYN, Chung HT, et al. Effect of recombinant alpha2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991; 78: 155163.
  • 8
    Lok ASF, Wu PC, Lai CL, Lau JYN, Leung EKY, Wong LSK, Ma OCK, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 20912097.
  • 9
    Chen D-S. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol 1993; 8: 470475.
  • 10
    Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Domsife RE, et al. The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (−) and (+) enantiomers of cis-5-fluoro-1-[2(hydroxymethyl)- 1,3-oxanthiolan-5-yl] cytosine. Antimicrob Agents Chemother 1992; 36: 26862692.
  • 11
    Chang CN, Doong S-L, Zhour JH, Beach JW, Jeong LS, Chu CK, Tsai CH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′3′-dideoxy-3-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267: 1393813942.
  • 12
    Tyrell DLJ, Fischer K, Savani K, Tan W, Jewell L. Treatment of chimpanzees and ducks with lamivudine, 2′,3′ dideoxy 3′ thiacytidine results in a rapid suppression of hepadna viral DNA in sera [Abstract]. Clin Invest Med 1993; 16: B77.
  • 13
    Gonzalez-Peralta R, Andres JM, Tung FY, Fang JWS, Brunson ME, Davis GL, Lau JYN. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation 1994; 58: 114116.
  • 14
    Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 16571661.
  • 15
    Tyrrell DLJ, Mitchell MC, De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, et al. Phase II trial of lamivudine for chronic hepatitis B [Abstract]. HEPATOLOGY 1993; 18: 112A.
  • 16
    McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 10991105.
  • 17
    Cui L, Yoon S, Schinazi RF, Sommadossi J-P. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95: 555563.
  • 18
    Perillo RP. Factors influencing response to interferon in hepatitis B. Implications for Asian and Western populations. HEPATOLOGY 1990; 12:14331434.